BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/8/2024 7:49:57 AM | Browse: 103 | Download: 667
 |
Received |
|
2024-01-24 07:29 |
|
Peer-Review Started |
|
2024-01-24 07:29 |
|
First Decision by Editorial Office Director |
|
2024-02-27 04:08 |
|
Return for Revision |
|
2024-02-27 04:08 |
|
Revised |
|
2024-03-05 08:54 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-04-23 23:59 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-04-30 09:48 |
|
Articles in Press |
|
2024-04-30 09:48 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-06-24 03:23 |
|
Publish the Manuscript Online |
|
2024-07-08 07:49 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Evaluation of teplizumab's efficacy and safety in treatment of type 1 diabetes mellitus: A systematic review and meta-analysis
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Xiao-Lan Ma, Dan Ge and Xue-Jian Hu |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Xue-Jian Hu, MM, Doctor, Doctor, Department of Endocrinology and Metabolism, The Second Affiliated Hospital of Lanzhou University, No. 82 Linxia Road, Lanzhou 730000, Gansu Province, China. xuejian2023@sina.com |
| Key Words |
Type-1 diabetes mellitus; Teplizumab; Anti-CD3 monoclonal antibody; Insulin; Glycated haemoglobin A1c; C-peptide |
| Core Tip |
Type 1 diabetes mellitus (T1DM) may benefit from teplizumab. However, there is limited data on its long-term effects on clinical T1DM development, safety, and efficacy. Given its perceived use, this research evaluated the effectiveness and safety of teplizumab for T1DM patients through a systematic review and meta-analysis of 8 randomized controlled trials, including 1908 patients from various age groups. It was found that teplizumab treatment results in reduced insulin use, improved C-peptide response, significant glycated haemoglobin A1c changes in T1DM patients with minimal side effects and improved glycaemic management. |
| Publish Date |
2024-07-08 07:49 |
| Citation |
Ma XL, Ge D, Hu XJ. Evaluation of teplizumab's efficacy and safety in treatment of type 1 diabetes mellitus: A systematic review and meta-analysis. World J Diabetes 2024; 15(7): 1615-1626 |
| URL |
https://www.wjgnet.com/1948-9358/full/v15/i7/1615.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v15.i7.1615 |
© 2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
